CORT — Corcept Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $2.37bn
- $2.00bn
- $482.38m
- 92
- 38
- 58
- 67
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 276 | 441 | 224 | 432 | 368 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 19.9 | 26.2 | 27.6 | 31.1 | 41.1 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 307 | 479 | 266 | 499 | 459 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 4.5 | 4.18 | 1.52 | 1.78 | 0.315 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 412 | 572 | 424 | 583 | 622 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 38.8 | 47.5 | 47.5 | 72.5 | 105 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 41.1 | 48.4 | 48 | 81.6 | 115 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 371 | 523 | 376 | 502 | 507 |
Total Liabilities & Shareholders' Equity | 412 | 572 | 424 | 583 | 622 |
Total Common Shares Outstanding |